ERX-1000 for Obesity
Identification Of ERX-1000: First-in-class Leptin Sensitizer
By using a systems-biology approach, ERX scientific co-founder Dr. Umut Ozcan identified ERX-1000, a first-in-class leptin sensitizer. While ERX-1000 is highly effective at reducing appetite and decreasing weight in diet-induced obese mouse models (an experimental model of human obesity), it does not have any effect on leptin-deficient obese mice, obese mice lacking leptin signaling (genetically deficient in leptin or its receptor), or non-obese mice, demonstrating that ERX-1000 is a true leptin sensitizer.
Preclinical Effects of ERX-1000
Administration of ERX-1000 in a preclinical laboratory setting to diet-induced severely obese mice reduced appetite up to 80% and led to a 45% decrease in bodyweight in 21 days, a level of weight loss that has not been previously observed in any drug in preclinical studies or in animal models of invasive bariatric surgery.
In additional preclinical studies in diet-induced severely obese mice, ERX-1000 demonstrated an effect on the energy metabolism of the body. Under normal conditions, when food intake is restricted, the brain reduces the body’s energy expenditure, which makes it more difficult to maintain weight loss. This has been one of the obstacles in promoting weight loss through diet alone. When the leptin system is functioning properly, leptin suppresses appetite and reduces food intake, while also blocking the brain’s signal to reduce energy expenditure. As a leptin sensitizer, ERX-1000 similarly blocks the messages to reduce energy expenditure in the body, which potentiates its effect on weight loss.
Burning Exclusively Fat
Generally, calorie restriction or diet-induced weight loss is accompanied by some reduction in the body’s muscle mass. However, in preclinical studies of ERX-1000 in diet-induced obese mice, weight loss was achieved through the utilization of fat stores and did not lead to a reduction in muscle mass.